Evaluation of sCD163 and sTWEAK in patients with stable peripheral arterial disease and association with disease severity as well as long-term mortality

Background and aimsThe TNF-superfamily member sTWEAK its scavenger receptor sCD163 are potentially involved in pathophysiological processes of atherosclerosis. In patients with peripheral arterial disease, previous research has shown that the sCD163/sTWEAK ratio were independently associated long term all-cause cardiovascular survival. Since investigations emphasized on symptomatic disease including critical limb ischemia, this study evaluates a cohort stable asymptomatic (Fontaine stage I) intermittent claudication II) patients.MethodssTWEAK concentrations 354 measured using commercially available ELISA kit. was quantified multiplex bead assay. Cox proportional hazards regression used to assess outcome after seven-year follow-up. Hazard ratios given as interquartile range.ResultsPatients exhibited increased levels comparison (p = 0.002). However, not related severity 0.740). A multivariable Cox-proportional hazard models risk factors (age, HbA1c, CRP, LDL-C, BMI, eGFR) revealed an inverse association mortality (HR 0.775 (95% CI 0.623–0.965) 0.710 0.534–0.944)). Further or showed no mortality.ConclusionsThis highlights use novel biomarker for PAD supports independent predictor even disease.